Novel benzene sulfonamide-piperazine hybrid compounds: design, synthesis, antioxidant, enzyme inhibition activities and docking, ADME profiling studies
Author:
Buran Kerem1, İnan Yiğit2, Uba Abdullahi Ibrahim3, Zengin Gökhan4
Affiliation:
1. Department of Pharmaceutical Chemistry , Hamidiye Faculty of Pharmacy, University of Health Sciences , Istanbul , 34668 , Türkiye 2. Department of Pharmacognosy , Hamidiye Faculty of Pharmacy, University of Health Sciences , Istanbul , 34668 , Türkiye 3. Department of Molecular Biology and Genetics , Istanbul AREL University , İstanbul , 34537 , Türkiye 4. Department of Biology, Science Faculty , Selcuk University , Konya , 42130 , Türkiye
Abstract
Abstract
Benzene sulfonamides are an important biological substituent for several activities. In this study, hybridization of benzene sulfonamide with piperazine derivatives were investigated for their antioxidant capacity and enzyme inhibitory potencies. Six molecules were synthesized and characterized. DPPH, ABTS, FRAP, CUPRAC, chelating and phosphomolybdemum assays were applied to evaluate antioxidant capacities. Results show that compounds have high antioxidant capacity and compound 4 has the best antioxidant activity among them. Compound 4 has higher antioxidant activity than references for FRAP (IC50: 0.08 mM), CUPRAC (IC50: 0.21 mM) and phosphomolybdenum (IC50: 0.22 mM) assays. Besides this, compound 4 has moderate DPPH and ABTS antioxidant capacity. Furthermore, enzyme inhibition activities of these molecules were investigated against AChE, BChE, tyrosinase, α-amylase and α-glucosidase enzymes. It was revealed that all compounds have good enzyme inhibitory potential except for α-amylase enzyme. The best inhibitory activities were observed for AChE with compound 5 the same value (IC50: 1.003 mM), for BChE with compounds 2 and 5 the same value (IC50: 1.008 mM), for tyrosinase compound 4 (IC50: 1.19 mM), and for α-glucosidase with compound 3 (IC50: 1.000 mM). Docking studies have been conducted with these molecules, and the results correlate well with the inhibitory assays.
Publisher
Walter de Gruyter GmbH
Reference31 articles.
1. Alzheimer’s Disease International. World Alzheimer report 2019: attitudes to dementia. London: Alzheimer’s Disease International (ADI); 2019. 2. Lolak, N, Boga, M, Tuneg, M, Karakoc, G, Akocak, S, Supuran, CT. Sulphonamides incorporating 1,3,5-triazine structural motifs show antioxidant, acetylcholinesterase, butyrylcholinesterase, and tyrosinase inhibitory profile. J Enzym Inhib Med Chem 2020;35:424–31. https://doi.org/10.1080/14756366.2019.1707196. 3. Bag, S, Tulsan, R, Sood, A, Cho, H, Redjeb, H, Zhou, W, et al.. Sulfonamides as multifunctional agents for Alzheimer’s disease. Bioorg Med Chem Lett 2015;25:626–30. https://doi.org/10.1016/j.bmcl.2014.12.006. 4. Mesulam, MM, Guillozet, A, Shaw, P, Levey, A, Duysen, EG, Lockridge, O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 2002;110:627–39. https://doi.org/10.1016/S0306-4522(01)00613-3. 5. Efferth, T, Zacchino, S, Georgiev, MI, Liu, L, Wagner, H, Panossian, A. Nobel prize for artemisinin brings phytotherapy into the spotlight. Phytomedicine 2015;22:A1–3. https://doi.org/10.1016/j.phymed.2015.10.003.
|
|